Income Tax Expense (Benefit) in USD of Ernexa Therapeutics Inc. from Q2 2010 to Q3 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary: Ernexa Therapeutics Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2010 to Q3 2025.
Ernexa Therapeutics Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was $6K, a 50% decline year-over-year.
Ernexa Therapeutics Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was $28K, a 86.7% increase year-over-year.
Ernexa Therapeutics Inc. annual Income Tax Expense (Benefit) for 2024 was $30K.
Ernexa Therapeutics Inc. annual Income Tax Expense (Benefit) for 2023 was -$3K, a 107% decline from 2022.
Ernexa Therapeutics Inc. annual Income Tax Expense (Benefit) for 2022 was $45K, a 29.7% decline from 2021.

Income Tax Expense (Benefit), Trailing 12 Months (USD)

Income Tax Expense (Benefit), Quarterly (USD)

Income Tax Expense (Benefit), YoY Quarterly Growth (%)

Income Tax Expense (Benefit), Annual (USD)

Income Tax Expense (Benefit), YoY Annual Growth (%)

Ernexa Therapeutics Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2025	$28K	$6K	-$6K	-50%	Jul 1, 2025	Sep 30, 2025	10-Q	2025-11-07
Q2 2025	$34K	$3K	$0	0%	Apr 1, 2025	Jun 30, 2025	10-Q	2025-08-13
Q1 2025	$34K	$8K	+$4K	+100%	Jan 1, 2025	Mar 31, 2025	10-Q	2025-05-07
Q4 2024	$30K	$11K	+$15K		Oct 1, 2024	Dec 31, 2024	10-K	2025-03-12
Q3 2024	$15K	$12K	+$20K		Jul 1, 2024	Sep 30, 2024	10-Q	2025-11-07
Q2 2024	-$5K	$3K	-$1K	-25%	Apr 1, 2024	Jun 30, 2024	10-Q	2025-08-13
Q1 2024	-$4K	$4K	-$1K	-20%	Jan 1, 2024	Mar 31, 2024	10-Q	2025-05-07
Q4 2023	-$3K	-$4K	-$44K	-110%	Oct 1, 2023	Dec 31, 2023	10-K	2025-03-12
Q3 2023	$41K	-$8K	-$13K	-260%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-11-12
Q2 2023	$54K	$4K	+$4K		Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-13
Q1 2023	$50K	$5K	+$5K		Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-14
Q4 2022	$45K	$40K			Oct 1, 2022	Dec 31, 2022	10-K	2024-03-14
Q3 2022		$5K	+$5K		Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-13
Q2 2022		$0			Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-11
Q1 2022		$0	$0		Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-11
Q3 2021		$0	+$19K		Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-14
Q1 2021	$19K	$0	+$19K		Jan 1, 2021	Mar 31, 2021	10-Q	2022-07-01
Q4 2020	$0	$23K			Oct 1, 2020	Dec 31, 2020	10-K/A	2022-07-01
Q3 2020		-$19K	-$38K	-200%	Jul 1, 2020	Sep 30, 2020	10-Q	2020-11-13
Q2 2020		$15K			Apr 1, 2020	Jun 30, 2020	10-Q	2020-08-07
Q1 2020		-$19K	-$30K	-273%	Jan 1, 2020	Mar 31, 2020	10-Q	2020-05-20
Q3 2019		$19K	+$9K	+90%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-13
Q1 2019	-$55K	$11K	+$9K	+450%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-20
Q4 2018	-$64K	-$100K	-$145K	-322%	Oct 1, 2018	Dec 31, 2018	10-K	2020-03-19
Q3 2018	$81K	$10K	+$1K	+11.1%	Jul 1, 2018	Sep 30, 2018	10-Q	2019-11-01
Q2 2018	$80K	$24K	+$18K	+300%	Apr 1, 2018	Jun 30, 2018	10-Q	2019-08-12
Q1 2018	$62K	$2K	-$4K	-66.7%	Jan 1, 2018	Mar 31, 2018	10-Q	2019-05-14
Q4 2017	$66K	$45K	+$38K	+543%	Oct 1, 2017	Dec 31, 2017	10-K	2019-03-22
Q3 2017	$28K	$9K	+$2K	+28.6%	Jul 1, 2017	Sep 30, 2017	10-Q	2018-11-09
Q2 2017	$26K	$6K	+$1K	+20%	Apr 1, 2017	Jun 30, 2017	10-Q	2018-08-06
Q1 2017	$25K	$6K	-$13K	-68.4%	Jan 1, 2017	Mar 31, 2017	10-Q	2018-05-11
Q4 2016	$38K	$7K	+$8K		Oct 1, 2016	Dec 31, 2016	10-K	2018-03-09
Q3 2016	$30K	$7K	+$22K		Jul 1, 2016	Sep 30, 2016	10-Q	2017-11-08
Q2 2016	$8K	$5K	-$9K	-64.3%	Apr 1, 2016	Jun 30, 2016	10-Q	2017-08-04
Q1 2016	$17K	$19K	+$5K	+35.7%	Jan 1, 2016	Mar 31, 2016	10-Q	2017-05-04
Q4 2015	$12K	-$1K	-$57K	-102%	Oct 1, 2015	Dec 31, 2015	10-K	2017-03-09
Q3 2015	$69K	-$15K	-$36K	-171%	Jul 1, 2015	Sep 30, 2015	10-Q	2016-11-09
Q2 2015	$105K	$14K	+$17K		Apr 1, 2015	Jun 30, 2015	10-Q	2016-08-04
Q1 2015	$88K	$14K	+$4K	+40%	Jan 1, 2015	Mar 31, 2015	10-Q	2016-05-09
Q4 2014	$84K	$56K	+$26K	+86.7%	Oct 1, 2014	Dec 31, 2014	10-K	2016-03-15
Q3 2014	$58K	$21K	+$18K	+600%	Jul 1, 2014	Sep 30, 2014	10-Q	2015-11-09
Q2 2014	$40K	-$3K	-$8K	-160%	Apr 1, 2014	Jun 30, 2014	10-Q	2015-08-10
Q1 2014	$48K	$10K	+$2K	+25%	Jan 1, 2014	Mar 31, 2014	10-Q	2015-05-08
Q4 2013	$46K	$30K	+$139K		Oct 1, 2013	Dec 31, 2013	10-K	2015-03-27
Q3 2013	-$93K	$3K	-$19K	-86.4%	Jul 1, 2013	Sep 30, 2013	10-Q	2014-11-07
Q2 2013	-$74K	$5K	+$17K		Apr 1, 2013	Jun 30, 2013	10-Q	2014-08-14
Q1 2013	-$91K	$8K	-$8K	-50%	Jan 1, 2013	Mar 31, 2013	10-Q	2014-05-15
Q4 2012	-$83K	-$109K			Oct 1, 2012	Dec 31, 2012	10-K	2014-03-31
Q3 2012		$22K	-$15K	-40.5%	Jul 1, 2012	Sep 30, 2012	10-Q	2013-11-14
Q2 2012		-$12K			Apr 1, 2012	Jun 30, 2012	10-Q	2013-08-14
Q1 2012		$16K	+$5K	+45.5%	Jan 1, 2012	Mar 31, 2012	10-Q	2013-05-13
Q3 2011		$37K	+$22K	+147%	Jul 1, 2011	Sep 30, 2011	10-Q	2012-11-09
Q1 2011		$11K			Jan 1, 2011	Mar 31, 2011	10-Q	2012-05-11
Q3 2010		$15K			Jul 1, 2010	Sep 30, 2010	10-Q	2011-11-14
Q2 2010		-$13K			Apr 1, 2010	Jun 30, 2010	10-Q	2011-08-12

Ernexa Therapeutics Inc. Annual Income Tax Expense (Benefit) (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
2024	$30K	+$33K		Jan 1, 2024	Dec 31, 2024	10-K	2025-03-12
2023	-$3K	-$48K	-107%	Jan 1, 2023	Dec 31, 2023	10-K	2025-03-12
2022	$45K	-$19K	-29.7%	Jan 1, 2022	Dec 31, 2022	10-K	2024-03-14
2021	$64K	+$64K		Jan 1, 2021	Dec 31, 2021	10-K	2023-03-20
2020	$0	-$27K	-100%	Jan 1, 2020	Dec 31, 2020	10-K/A	2022-07-01
2019	$27K	+$91K		Jan 1, 2019	Dec 31, 2019	10-K	2021-03-11
2018	-$64K	-$130K	-197%	Jan 1, 2018	Dec 31, 2018	10-K	2020-03-19
2017	$66K	+$28K	+73.7%	Jan 1, 2017	Dec 31, 2017	10-K	2019-03-22
2016	$38K	+$26K	+217%	Jan 1, 2016	Dec 31, 2016	10-K	2018-03-09
2015	$12K	-$72K	-85.7%	Jan 1, 2015	Dec 31, 2015	10-K	2017-03-09
2014	$84K	+$38K	+82.6%	Jan 1, 2014	Dec 31, 2014	10-K	2016-03-15
2013	$46K	+$129K		Jan 1, 2013	Dec 31, 2013	10-K	2015-03-27
2012	-$83K	-$246K	-151%	Jan 1, 2012	Dec 31, 2012	10-K	2014-03-31
2011	$163K	+$121K	+288%	Jan 1, 2011	Dec 31, 2011	10-K	2013-03-29
2010	$42K			Jan 1, 2010	Dec 31, 2010	10-K	2012-03-30

* An asterisk sign (*) next to the value indicates that the value is likely invalid.